Abstract
Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Original language | English |
---|---|
Pages (from-to) | 2940-2947 |
Number of pages | 8 |
Journal | Current Pharmaceutical Design |
Volume | 17 |
Issue number | 27 |
DOIs | |
Publication status | Published - Sept-2011 |
Keywords
- Tuberculosis
- central nervous system
- tuberculous meningitis
- antituberculosis agents
- blood-brain barrier
- corticosteroids
- thalidomide
- adverse neurotoxic effects
- EARLY BACTERICIDAL ACTIVITY
- CEREBROSPINAL-FLUID
- PULMONARY TUBERCULOSIS
- RESISTANT TUBERCULOSIS
- RETROSPECTIVE ANALYSIS
- MULTIDRUG-RESISTANT
- MYASTHENIC SYNDROME
- OCULAR TOXICITY
- OPTIC NEURITIS
- SHUNT SURGERY